Polyisocyanates and Their Prepolymers

Asthma in the Workplace and Related Conditions: Third Edition

Volumn , Issue , 2006, Pages 481-504

  Wisnewski, Adam V ^a   Redlich, Carrie A ^a   Mapp, Cristina E ^b   Bernstein, David I ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136369095     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849374531-24     Document Type: Chapter

References (169)

1. Redlich CA, Karol MH. Diisocyanate asthma: clinical aspects and immunopatho-genesis. Int Immunopharmacol 2002; 2(2-3):213-224.
2. Mapp C, Butcher BT, Fabbri LM. In: Bernstein D, ed. Polyisocyanates and their prepolymers 1st ed. 2001.
3. Chan-Yeung M, Malo JL, Tarlo SM, et al. Proceedings of the first Jack Pepys Occupational Asthma Symposium. Am J Respir Crit Care Med 2003; 167(3):450-471.
4. Urlich H. Chemistry and Technology of Isocyanates. England: John Wiley & Sons Ltd., 1996.
5. Stowe M, Winewski AV, Holm CT, et al. Cross-sectional study of auto body workers exposed to isocyanates: immunologic responses. Am J Resp Crit Care Med 2005; 171(A).
6. Woskie SR, Sparer J, Gore RJ, et al. Determinants of isocyanate exposures in auto body repair and refinishing shops. Ann Occup Hyg 2004; 48(5):393-403.
7. Sparer J, Stowe MH, Bello D, et al. Isocyanate exposures in autobody shop work: the SPRAY study. J Occup Environ Hyg 2004; 1(9):570-581.
8. Lofgren DJ, Walley TL, Peters PM, Weis ML. MDI exposure for spray-on truck bed lining. Appl Occup Environ Hyg 2003; 18(10):772-779.
9. Fabbri LM, Danieli D, Crescioli S, et al. Fatal asthma in a subject sensitized to toluene diisocyanate. Am Rev Respir Dis 1988; 137(6):1494—1498.
10. Redlich CA, Stowe MH, Coren BA, Wisnewski AV, Holm CT, Cullen MR. Diisocyanate-exposed auto body shop workers: a one-year follow-up. Am J Ind Med 2002; 42(6): 511-518.
11. Redlich CA, Stowe MH, Wisnewski AV, et al. Subclinical immunologic and physiologic responses in hexamethylene diisocyanate-exposed auto body shop workers. Am J Ind Med 2001; 39(6):587-597.
12. Tse KS, Johnson A, Chan H, Chan-Yeung M. A study of serum antibody activity in workers with occupational exposure to diphenylmethane diisocyanate. Allergy 1985; 40(5):314-320.
13. Welinder H, Nielsen J, Bensryd I, Skerfving S. IgG antibodies against polyisocyanates in car painters. Clin Allergy 1988; 18(1):85-93.
14. White WG, Morris MJ, Sugden E, Zapata E. Isocyanate-induced asthma in a car factory. Lancet 1980; 1(8171):756-760.
15. Carino M, Aliani M, Licitra C, Sarno N, Ioli F. Death due to asthma at workplace in a diphenylmethane diisocyanate-sensitized subject. Respiration 1997; 64(1):111-113.
16. Liss GM, Bernstein DI, Moller DR, Gallagher JS, Stephenson RL, Bernstein IL. Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol 1988; 82(1):55-61.
17. Zammit-Tabona M, Sherkin M, Kijek K, Chan H, Chan-Yeung M. Asthma caused by diphenylmethane diisocyanate in foundry workers. Clinical, bronchial provocation, and immunologic studies. Am Rev Respir Dis 1983; 128(2):226-230.
18. Petsonk EL, Wang ML, Lewis DM, Siegel PD, Husberg BJ. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118(4):1183-1193.
19. Krone CA, Klingner TD, Ely JT. Polyurethanes and childhood asthma. Med Sci Monit 2003; 9(12):HY39-HY43.
20. Fuchs S, Valade P. Clinical and experimental study of some cases of poisoning by desmodur T (1-2-4 and 1-2-6 di-isocyanates of toluene). Arch Mal Prof 1951; 12(2): 191-196.
21. Friebel H, Luchtrath H. Effects of toluylene diisocyanate (desmodur T) on the respira-tory tract. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1955; 227(2):93-110.
22. Swensson A, Holmquist CE, Lundgren KD. Injury to the respiratory tract by isocyanates used in making lacquers. Br J Ind Med 1955; 12(1):50-53.
23. Woodbury JW. Asthmatic syndrome following exposure to tolylene diisocyanate. Ind Med Surg 1956; 25(11):540-543.
24. Hama GM. Symptoms in workers exposed to isocyanates; suggested exposure concen-trations. AMA Arch Ind Health 1957; 16(3):232-233.
25. Johnstone RT. Toluene-2, 4-diisocyanate; clinical features. Ind Med Surg 1957; 26(1): 33-34.
26. Zapp JA Jr. Hazards of isocyanates in polyurethane foam plastic production. AMA Arch Ind Health 1957; 15(4):324-330.
27. Walworth HT, Virchow WE. Industrial hygiene experiences with toluene diisocyanate. Am Ind Hyg Assoc J 1959; 20(3):205-210.
28. Kessler RC. Pulmonary sensitization to toluene diisocyanate. J Occup Med 1960; 2: 143-147.
29. Elkins HB, McCarl GW, Brugsch HG, Fahy JP. Massachusetts experience with toluene di-isocyanate. Am Ind Hyg Assoc J 1962; 23:265-272.
30. Brugsch HG, Elkins HB. Toluene di-isocyanate (TDI) toxicity. N Engl J Med 1963; 268:353-357.
31. Konzen RB, Craft BF, Scheel LD, Gorski CH. Human response to low concentra-tions of p,p-diphenylmethane diisocyanate (MDI). Am Ind Hyg Assoc J 1966; 27(2): 121-127.
32. Baur X, Chen Z, Marczynski B. Respiratory diseases caused by occupational exposure to 1,5-naphthalene-diisocyanate (NDI): results of workplace-related challenge tests and antibody analyses. Am J Ind Med 2001; 39(4):369-372.
33. Diem JE, Jones RN, Hendrick DJ, et al. Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis 1982; 126(3):420-428.
34. Butcher BT, Jones RN, O’Neil CE, et al. Longitudinal study of workers employed in the manufacture of toluene-diisocyanate. Am Rev Respir Dis 1977; 116(3):411-421.
35. Peters JM, Wegman DH. Epidemiology of toluene diisocyanate (TDI)-induced respira-tory disease. Environ Health Perspect 1975; 11:97-100.
36. Seguin P, Allard A, Cartier A, Malo JL. Prevalence of occupational asthma in spray painters exposed to several types of isocyanates, including polymethylene polyphenyli-socyanate. J Occup Med 1987; 29(4):340-344.
37. Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM. Occupational asthma and extrinsic alveolitis due to isocyanates: current status and perspectives. Br J Ind Med 1993; 50(3):213-228.
38. Wild DM, Redlich CA, Paltiel AD. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occup Environ Med 2005; 62(11):743-749.
39. Bello D, Woskie SR, Streicher RP, et al. Polyisocyanates in occupational environments: a critical review of exposure limits and metrics. Am J Ind Med 2004; 46(5):480-491.
40. Weill H. Disaster at Bhopal: the accident, early findings and respiratory health outlook in those injured. Bull Eur Physiopathol Respir 1987; 23(6):587-590.
41. Luo JC, Nelsen KG, Fischbein A. Persistent reactive airway dysfunction syndrome after exposure to toluene diisocyanate. Br J Ind Med 1990; 47(4):239-241.
42. Butcher BT, Karr RM, O’Neil CE, et al. Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers. J Allergy Clin Immunol 1979; 64(2):146-152.
43. Mapp CE, Boschetto P, Dal Vecchio L, Maestrelli P, Fabbri LM. Occupational asthma due to isocyanates. Eur Respir J 1988; 1(3):273-279.
44. Littorin M, Welinder H, Skarping G, Dalene M, Skerfving S. Exposure and nasal inflammation in workers heating polyurethane. Int Arch Occup Environ Health 2002; 75(7):468-474.
45. Sari-Minodier I, Charpin D, Signouret M, Poyen D, Vervloet D. Prevalence of self-reported respiratory symptoms in workers exposed to isocyanates. J Occup Environ Med 1999; 41(7):582-588.
46. Durham SR, Graneek BJ, Hawkins R, Taylor AJ. The temporal relationship between increases in airway responsiveness to histamine and late asthmatic responses induced by occupational agents. J Allergy Clin Immunol 1987; 79(2):398-406.
47. Mapp CE, Dal Vecchio L, Boschetto P, De Marzo N, Fabbri LM. Toluene diisocyanate-induced asthma without airway hyperresponsiveness. Eur J Respir Dis 1986; 68(2): 89-95.
48. Karol MH, Tollerud DJ, Campbell TP, et al. Predictive value of airways hyperresponsiveness and circulating IgE for identifying types of responses to toluene diisocyanate inhalation challenge. Am J Respir Crit Care Med 1994; 149(3 Pt 1):611-615.
49. Bernstein DI, Korbee L, Stauder T, et al. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engi-neered for minimal exposure to diisocyanates. J Allergy Clin Immunol 1993; 92(3): 387-396.
50. Banks DE, Rando RJ, Barkman HW Jr. Persistence of toluene diisocyanate-induced asthma despite negligible workplace exposures. Chest 1990; 97(1):121-125.
51. Allard C, Cartier A, Ghezzo H, Malo JL. Occupational asthma due to various agents. Absence of clinical and functional improvement at an interval of four or more years after cessation of exposure. Chest 1989; 96(5):1046-1049.
52. Moller DR, McKay RT, Bernstein IL, Brooks SM. Persistent airways disease caused by toluene diisocyanate. Am Rev Respir Dis 1986; 134(1):175-176.
53. Mapp CE, Corona PC, De Marzo N, Fabbri L. Persistent asthma due to isocyanates. A follow-up study of subjects with occupational asthma due to toluene diisocyanate (TDI). Am Rev Respir Dis 1988; 137(6):1326-1329.
54. Paggiaro P, Bacci E, Paoletti P, et al. Bronchoalveolar lavage and morphology of the airways after cessation of exposure in asthmatic subjects sensitized to toluene diisocya-nate. Chest 1990; 98(3):536-542.
55. Piirila PL, Nordman H, Keskinen HM, et al. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate-, and toluene diisocyanate-induced asthma. Am J Respir Crit Care Med 2000; 162(2 Pt 1):516-522.
56. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. Eur Respir J 2003; 22(4):689-697.
57. Moscato G, Dellabianca A, Perfetti L, et al. Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999; 115(1):249-256.
58. Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to ‘‘sensitisation’’ to isocyanates? Thorax 1998; 53(2):152-153.
59. Clark RL, Bugler J, Paddle GM, Chamberlain JD, Allport DC. A 17-year epidemiolo-gical study on changes in lung function in toluene diisocyanate foam workers. Int Arch Occup Environ Health 2003; 76(4):295-301.
60. Clark RL, Bugler J, McDermott M, Hill ID, Allport DC, Chamberlain JD. An epide-miology study of lung function changes of toluene diisocyanate foam workers in the United Kingdom. Int Arch Occup Environ Health 1998; 71(3):169-179.
61. Ott MG, Klees JE, Poche SL. Respiratory health surveillance in a toluene di-isocyanate production unit 1967-97: clinical observations and lung function analyses. Occup Environ Med 2000; 57(1):43-52.
62. Woellner RC, Hall S, Greaves I, Schoenwetter WF. Epidemic of asthma in a wood products plant using methylene diphenyl diisocyanate. Am J Ind Med 1997; 31(1):56-63.
63. Musk AW, Peters JM, Wegman DH. Isocyanates and respiratory disease: current status. Am J Ind Med 1988; 13(3):331-349.
64. Simpson C, Garabrant D, Torrey S, Robins T, Franzblau A. Hypersensitivity pneumonitis-like reaction and occupational asthma associated with 1,3-bis(isocyanato-methyl) cyclohexane pre-polymer. Am J Ind Med 1996; 30(1):48-55.
65. Wegman DH, Musk AW, Main DM, Pagnotto LD. Accelerated loss of FEV- in poly-urethane production workers: a four-year prospective study. Am J Ind Med 1982; 3(2):209-215.
66. Akbar-Khanzadeh F, Rivas RD. Exposure to isocyanates and organic solvents, and pulmonary-function changes in workers in a polyurethane molding process. J Occup Environ Med 1996; 38(12):1205-1212.
67. Diller WF. Frequency and trends of occupational asthma due to toluene diisocyanate: a critical review. Appl Occup Environ Hyg 2002; 17(12):872-877.
68. Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med 2002; 59(1):58-62.
69. Kennedy AL, Wilson TR, Stock MF, Alarie Y, Brown WE. Distribution and reactivity of inhaled 14C-labeled toluene diisocyanate (TDI) in rats. Arch Toxicol 1994; 68(7):434-443.
70. Kennedy AL, Stock MF, Alarie Y, Brown WE. Uptake and distribution of 14C during and following inhalation exposure to radioactive toluene diisocyanate. Toxicol Appl Pharmacol 1989; 100(2):280-292.
71. Wisnewski AV, Srivastava R, Herick C, et al. Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo. Am J Respir Crit Care Med 2000; 162(6):2330-2336.
72. Monso E, Cloutier Y, Lesage J, Perreault G, Malo JL. What is the respiratory retention of inhaled hexamethylene di-isocyanate? Eur Respir J 2000; 16(4):729-730.
73. Liu Y, Berode M, Stowe MH, et al. Urinary hexane diamine to assess respiratory expo-sure to hexamethylene diisocyanate aerosol: a human inhalation study. Int J Occup Environ Health 2004; 10(3):262-271.
74. Johannesson G, Sennbro CJ, Willix P, Lindh CH, Jonsson BA. Identification and characterisation of adducts between serum albumin and 4,4'-methylenediphenyl diisocyanate (MDI) in human plasma. Arch Toxicol 2004; 78(7):378-383.
75. Sennbro CJ, Lindh CH, Tinnerberg H, et al. Development, validation and characteriza-tion of an analytical method for the quantification of hydrolysable urinary metabolites and plasma protein adducts of 2,4- and 2,6-toluene diisocyanate, 1,5-naphthalene diisocyanate and 4,4'-methylenediphenyl diisocyanate. Biomarkers 2003; 8(3-4):204-217.
76. Wisnewski AV, Lemus R, Karol MH, Redlich CA. Isocyanate-conjugated human lung epithelial cell proteins: a link between exposure and asthma? J Allergy Clin Immunol 1999; 104(2 Pt 1):341-347.
77. Matheson JM, Lemus R, Lange RW, Karol MH, Luster MI. Role of tumor necrosis factor in toluene diisocyanate asthma. Am J Respir Cell Mol Biol 2002; 27(4):396-405.
78. Lemiere C, Pelissier S, Tremblay C, et al. Leukotrienes and isocyanate-induced asthma: a pilot study. Clin Exp Allergy 2004; 34(11):1684-1689.
79. Maestrelli P, Calcagni PG, Saetta M, et al. Sputum eosinophilia after asthmatic responses induced by isocyanates in sensitized subjects. Clin Exp Allergy 1994; 24(1):29-34.
80. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326(5):298-304.
81. Park H, Jung K, Kim H, Nahm D, Kang K. Neutrophil activation following TDI bronchial challenges to the airway secretion from subjects with TDI-induced asthma. Clin Exp Allergy 1999; 29(10):1395-1401.
82. Sastre J, Banks DE, Lopez M, Barkman HW, Salvaggio JE. Neutrophil chemotactic activity in toluene diisocyanate (TDI)-induced asthma. J Allergy Clin Immunol 1990; 85(3):567-572.
83. Valentino M, Governa M, Fiorini R. Increased neutrophil leukocyte chemotaxis induced by release of a serum factor in toluene-diisocyanate (TDI) asthma. Lung 1988; 166(6):317-325.
84. Fabbri LM, Boschetto P, Zocca E, et al. Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis 1987; 136(1): 36-42.
85. Bentley AM, Maestrelli P, Saetta M, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992; 89(4):821-829.
86. Shi HZ, Li S, Xie ZF, Qin XJ, Qin X, Zhong XN. Regulatory CD4+CD25+ T lymphocytes in peripheral blood from patients with atopic asthma. Clin Immunol 2004; 113(2):172-178.
87. Del Prete GF, De Carli M, D’Elios MM, et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23(7):1445-1449.
88. Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994; 20(5):376-381.
89. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate. Clin Exp Allergy 1997; 27(11): 1292-1298.
90. Herrick CA, Xu L, Wisnewski AV, Das J, Redlich CA, Bottomly K. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J Allergy Clin Immunol 2002; 109(5):873-878.
91. Liu Q, Wisnewski AV. Recent developments in diisocyanate asthma. Ann Allergy Asthma Immunol 2003; 90(5 suppl 2):35-41.
92. Wisnewski AV, Herrick CA, Liu Q, Chen L, Bottomly K, Redlich CA. Human gamma/ delta T-cell proliferation and IFN-gamma production induced by hexamethylene diiso-cyanate. J Allergy Clin Immunol 2003; 112(3):538-546.
93. Redlich CA, Karol MH, Graham C, et al. Airway isocyanate-adducts in asthma induced by exposure to hexamethylene diisocyanate. Scand J Work Environ Health 1997; 23(3):227-231.
94. Choi JH, Nahm DH, Kim SH, et al. Increased levels of IgG to cytokeratin 19 in sera of patients with toluene diisocyanate-induced asthma. Ann Allergy Asthma Immunol 2004; 93(3):293-298.
95. Finotto S, Fabbri LM, Rado V, Mapp CE, Maestrelli P. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br J Ind Med 1991; 48(2):116-121.
96. Bernstein JA, Munson J, Lummus ZL, Balakrishnan K, Leikauf G. T-cell receptor V beta gene segment expression in diisocyanate-induced occupational asthma. J Allergy Clin Immunol 1997; 99(2):245-250.
97. Lummus ZL, Alam R, Bernstein JA, Bernstein DI. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol 1998; 102(2):265-274.
98. Bernstein DI, Cartier A, Cote J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002; 166(4): 445-450.
99. Mapp CE, Beghe B, Balboni A, et al. Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma. Clin Exp Allergy 2000; 30(5):651-656.
100. Nel AE, Slaughter N. T-cell activation through the antigen receptor. Part 2: role of signaling cascades in T-cell differentiation, anergy, immune senescence, and develop-ment of immunotherapy. J Allergy Clin Immunol 2002; 109(6):901-915.
101. Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol 2002; 109(5):758-770.
102. Mapp CE. The role of genetic factors in occupational asthma. Eur Respir J 2003; 22(1):173-178.
103. Piirila P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11(5):437-445.
104. Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109(5):867-872.
105. Wikman H, Piirila P, Rosenberg C, et al. N-Acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics 2002; 12(3):227-233.
106. Berode M, Jost M, Ruegger M, Savolainen H. Host factors in occupational diisocyanate asthma: a Swiss longitudinal study. Int Arch Occup Environ Health 2005; 78(2): 158-163.
107. Day BW, Jin R, Basalyga DM, Kramarik JA, Karol MH. Formation, solvolysis, and transcarbamoylation reactions of bis(S-glutathionyl) adducts of 2,4- and 2,6-diisocyana-totoluene. Chem Res Toxicol 1997; 10(4):424-431.
108. Lange RW, Day BW, Lemus R, Tyurin VA, Kagan VE, Karol MH. Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene. Chem Res Toxicol 1999; 12(10):931-936.
109. Lantz RC, Lemus R, Lange RW, Karol MH. Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of toluene diisocyanate. Toxicol Sci 2001; 60(2):348-355.
110. Pauluhn J. Inhalation toxicity of 1,6-hexamethylene diisocyanate homopolymer (HDI-IC) aerosol: results of single inhalation exposure studies. Toxicol Sci 2000; 58(1):173-181.
111. Pauluhn J. Acute inhalation toxicity of polymeric diphenyl-methane 4,4'-diisocyanate in rats: timecourseof changes in bronchoalveolar lavage. Arch Toxicol 2000; 74(4-5):257-269.
112. Wisnewski AV, Liu Q, Liu J, Redlich CA. Glutathione protects human airway proteins and epithelial cells from isocyanates. Clin Exp Allergy 2005; 35(3):325-327.
113. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002; 234-235(1-2):239-248.
114. Rahman I, Mulier B, Gilmour PS, et al. Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB. Biochem Pharmacol 2001; 62(6):787-794.
115. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16(3):534-554.
116. Wisnewski AV, Liu Q, Miller JJ, Magoski N, Redlich CA. Effects of hexamethylene diisocyanate exposure on human airway epithelial cells: in vitro cellular and molecular studies. Environ Health Perspect 2002; 110(9):901-907.
117. Iwata S, Hori T, Sato N, et al. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J Immunol 1997; 158(7):3108-3117.
118. Wakasugi N, Tagaya Y, Wakasugi H, et al. Adult T-cell leukemia-derived factor/ thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 1990; 87(21):8282-8286.
119. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994; 1218(3):292-296.
120. Elms J, Beckett PN, Griffin P, Curran AD. Mechanisms of isocyanate sensitisation. An in vitro approach. Toxicol In Vitro 2001; 15(6):631-634.
121. Tse CS, Pesce AJ. Chemical characterization of isocyanate-protein conjugates. Toxicol Appl Pharmacol 1979; 51:39-46.
122. Lee KS, Jin SM, Kim SS, Lee YC. Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2004; 113(5):902-909.
123. Lee YC, Song CH, Lee HB, et al. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol 2001; 108(6):1021-1026.
124. Matheson JM, Johnson VJ, Luster MI. Immune mediators in a murine model for occupational asthma: studies with toluene diisocyanate. Toxicol Sci 2005; 84(1):99-109.
125. Matheson JM, Lange RW, Lemus R, Karol MH, Luster MI. Importance of inflammatory and immune components in a mouse model of airway reactivity to toluene diisocyanate (TDI). Clin Exp Allergy 2001; 31(7):1067-1076.
126. Vanoirbeek JA, Tarkowski M, Ceuppens JL, Verbeken EK, Nemery B, Hoet PH. Respiratory response to toluene diisocyanate depends on prior frequency and concen-tration of dermal sensitization in mice. Toxicol Sci 2004; 80(2):310-321.
127. Bernstein DI, Jolly A. Current diagnostic methods for diisocyanate induced occupa-tional asthma. Am J Ind Med 1999; 36(4):459-468.
128. Rammazzini B. De Morbis Artifictum Diatriba. In: Wright WC, ed. Translated from Latin Text. New York: Hafner, 1964.
129. Pepys J, Hutchcroft BJ. Bronchial provocation tests in etiologic diagnosis and analysis of asthma. Am Rev Res Dis 1975; 112(6):829-859.
130. Darcey D, Lipscomb HJ, Epling C, Pate W, Cherry LP, Bernstein J. Clinical findings for residents near a polyurethane foam manufacturing plant. Arch Environ Health 2002; 57(3):239-246.
131. Merget R, Marczynski B, Chen Z, et al. Haemorrhagic hypersensitivity pneumonitis due to naphthylene-1,5-diisocyanate. Eur Respir J 2002; 19(2):377-380.
132. Yoshizawa Y, Ohtani Y, Hayakawa H, Sato A, Suga M, Ando M. Chronic hypersensi-tivity pneumonitis in Japan: a nationwide epidemiologic survey. J Allergy Clin Immunol 1999; 103(2 Pt 1):315-320.
133. Buick JB, Todd GR. Concomitant alveolitis and asthma following exposure to triphe-nylmethane triisocyanate. Occup Med (Lond) 1997; 47(8):504-506.
134. Baur X. Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocya-nates. J Allergy Clin Immunol 1995; 95(5 Pt 1):1004-1010.
135. Baur X, Chen Z, Flagge A, Posch A, Raulf-Heimsoth M. EAST and CAP specificity for the evaluation of IgE and IgG antibodies to diisocyanate-HSA conjugates. Int Arch Allergy Immunol 1996; 110(4):332-338.
136. Baur X, Dewair M, Fruhmann G. Detection of immunologically sensitized isocyanate workers by RAST and intracutaneous skin tests. J Allergy Clin Immunol 1984; 73(5 Pt 1):610-618.
137. Tee RD, Cullinan P, Welch J, Burge PS, Newman-Taylor AJ. Specific IgE to isocya-nates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101(5):709-715.
138. Lushniak BD, Reh CM, Bernstein DI, Gallagher JS. Indirect assessment of 4,4'-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med 1998; 33(5):471-477.
139. Lemus R, Lukinskeine L, Bier ME, Wisnewski AV, Redlich CA, Karol MH. Development of immunoassays for biomonitoring of hexamethylene diisocyanate exposure. Environ Health Perspect 2001; 109(11):1103-1108.
140. Karol MH, Alarie Y. Antigens which detect IgE antibodies in workers sensitive to toluene diisocyanate. Clin Allergy 1980; 10(1):101-109.
141. Karol MH, Hauth BA. Use of hexyl isocyanate antigen to detect antibodies to hexam-ethylene diisocyanate (HDI) in sensitized guinea pigs and in a sensitized worker. Fundam Appl Toxicol 1982; 2(3):108-113.
142. Karol MH, Alarie YC. Serologic test for toluene diisocyanate (TDI) antibodies (letter). J Occup Med 1978; 20(6):383.
143. Karol MH, Ioset HH, Alarie YC. Tolyl-specific IgE antibodies in workers with hyper-sensitivity to toluene diisocyanate. Am Ind Hyg Assoc J 1978; 39(6):454-458.
144. Karol MH, Riley EJ, Alarie Y. Presence of tolyl-specific IgE and absence of IgG antibodies in workers exposed to toluene diisocyanate. J Environ Sci Health C: Environ Health Sci 1979; 13(3):221-232.
145. Karol MH, Sandberg T, Riley EJ, Alarie Y. Longitudinal study of tolyl-reactive IgE antibodies in workers hypersensitive to TDI. J Occup Med 1979; 21(5):354-358.
146. Scheel LD, Killens R, Josephson A. Immunochemical aspects of toluene diisocyanate (TDI) toxicity. Am Ind Hyg Assoc J 1964; 25:179-184.
147. Wisnewski AV, Stowe MH, Cartier A, et al. Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol 2004; 113(6):1178-1184.
148. Avery SB, Stetson DM, Pan PM, Mathews KP. Immunological investigation of indivi-duals with toluene diisocyanate asthma. Clin Exp Immunol 1969; 4(5):585-596.
149. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171(1):54-60.
150. Mapp CE, Polato R, Maestrelli P, Hendrick DJ, Fabbri LM. Time course of the increase in airway responsiveness associated with late asthmatic reactions to toluene diisocyanate in sensitized subjects. J Allergy Clin Immunol 1985; 75(5):568-572.
151. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 53-83.
152. Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10(11):2612-2629.
153. Butcher BT, Hammad YY, Hendrick DJ. Occupational asthma: identification in the agent. In: Gee JBL, ed. Occupational Lung Disease. New York: Churchill Livingstone, 1984:111.
154. Fabbri LM. Occupational Asthma. In: O’Bryne PM, ed. Asthma as an Inflammatory Disease. New York: Marcel Dekker, Inc., 1990.
155. Tarlo SM, Boulet LP, Cartier A, et al. Canadian Thoracic Society guidelines for occupational asthma. Can Respir J 1998; 5(4):289-300.
156. Banks DE, Sastre J, Butcher BT, et al. Role of inhalation challenge testing in the diag-nosis of isocyanate-induced asthma. Chest 1989; 95(2):414-423.
157. Nicholson PJ, Cullinan P, Taylor AJ, Burge PS, Boyle C. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62(5):290-299.
158. Burge PS, O’Brien IM, Harries MG. Peak flow rate records in the diagnosis of occupational asthma due to isocyanates. Thorax 1979; 34(3):317-323.
159. Perrin B, Lagier F, L’Archeveque J, et al. Occupational asthma: validity of monitoring of peak expiratory flow rates and non-allergic bronchial responsiveness as compared to specific inhalation challenge. Eur Respir J 1992; 5(1):40-48.
160. Malo JL, Cartier A, Ghezzo H, Chan-Yeung M. Compliance with peak expiratory flow readings affects the within- and between-reader reproducibility of interpretation of graphs in subjects investigated for occupational asthma. J Allergy Clin Immunol 1996; 98(6 Pt 1):1132-1134.
161. Tarlo SM, Liss GM. Diisocyanate-induced asthma: diagnosis, prognosis, and effects of medical surveillance measures. Appl Occup Environ Hyg 2002; 17(12):902-908.
162. Tarlo SM, Liss GM. Occupational asthma: an approach to diagnosis and management. Cmaj 2003; 168(7):867-871.
163. Sheffer AL, Silverman M, Woolcock AJ, Diaz PV, Lindberg B, Lindmark B. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol 2005; 94(1):48-54.
164. Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 2003; 123(6):1908-1915.
165. Blake KV. Drug treatment of airway inflammation in asthma. Pharmacotherapy 2001; 21(3 Pt 2):3S-20S.
166. Fabbri LM, Chiesura-Corona P, Dal Vecchio L, et al. Prednisone inhibits late asth-matic reactions and the associated increase in airway responsiveness induced by toluene-diisocyanate in sensitized subjects. Am Rev Respir Dis 1985; 132(5): 1010-1014.
167. Fabbri LM, Di Giacomo R, Dal Vecchio L, et al. Prednisone, indomethacin and airway responsiveness in toluene diisocyanate sensitized subjects. Bull Eur Physiopathol Respir 1985; 21(5):421-426.
168. Mapp C, Boschetto P, dal Vecchio L, et al. Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocya-nate in sensitized subjects. Am Rev Respir Dis 1987; 136(6):1403-1407.
169. Tossin L, Chiesura-Corona P, Fabbri LM, et al. Ketotifen does not inhibit asthmatic reactions induced by toluene di-isocyanate in sensitized subjects. Clin Exp Allergy 1989; 19(2):177-182.